Results 271 to 280 of about 435,241 (348)

Information behavior patterns and subjective digital well‐being: An exploratory study on perceptions of adults living in Germany

open access: yesJournal of the Association for Information Science and Technology, EarlyView.
Abstract This exploratory study examines patterns of digital information behaviors such as information seeking, use, sharing, evaluation, avoidance, and curation to determine how they relate to subjective digital well‐being. To explore adults' personal views on their digital well‐being, conceptualized here as subjective digital well‐being, this study ...
Leyla Dewitz
wiley   +1 more source

How does geographical diversity shape vaccine efficacy? [PDF]

open access: yesClin Exp Vaccine Res
Abavisani M   +3 more
europepmc   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani   +4 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy